Business & Regulation

Welcome to The Power List 2016

Innovation is increasingly coming from small biotechs, but such companies rely on external funding to develop the compounds. A solid regulatory strategy is essential to convince investors to fund the further development.

Sitting Down With... Christian Schneider, Director of the National Institute for Biological Standards and Control (NIBSC), UK.

The use and misuse of antibiotics is a major driver behind the drug-resistance problem, but large environmental discharges of antibiotics from pharma manufacturing can also contribute. It’s time for companies to live up to their ethical responsibilities.

Sir Andrew Witty seeks to cement his legacy as GSK addresses patents and medicines access in the developing world

A newly introduced tax law in the US puts an end to the would-be mega-merger between Pfizer and Allergan

The Power List is back, but is it a fair representation of the male to female ratio in our industry?

Despite controversies, Robert Califf will finally take the reins at the FDA.

A new study estimates that 11.6 billion euros’ worth of goods are being stolen across Europe each year – but what about pharmaceuticals?

Collaboration can be the key to success, but does open innovation truly unlock the right doors?